StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Lisdexamfetamine Dimesylate

HCID 11597697
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
608137-33-3
Standard-SMILES
CS(=O)(=O)O.CS(=O)(=O)O.C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN
InChIKey
CETWSOHVEGTIBR-FORAGAHYSA-N
Summenformel
C17H33N3O7S2
Durchschnittliche Molmasse
455,6 g/mol
Monoisotopische Masse
455,17599275

Überblick

Lisdexamfetamine Dimesylate is the dimesylate form and prodrug of the d-isomer of amphetamine, a non-catecholamine sympathomimetic amine with central nervous system (CNS) stimulating activity. Upon administration, lisdexamphetamine is converted to dextroamphetamine through cleavage of the lysine group. Dextroamphetamine acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from its storage sites in nerve terminals in the CNS, and inhibits their uptake within the mesocorticolimbic system, a major component of the brain reward system, resulting in measurable behavioral changes such as euphoria, mental alertness and excitement and appetite suppression. As a CNS stimulant, this agent may increase blood pressure.

Namen und Bezeichner

Bevorzugter Name
Lisdexamfetamine Dimesylate
IUPAC
(2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide;methanesulfonic acid
Englischer Name
(2S)-2,6-Diamino-N-[(1S)-1-methyl-2-phenylethyl]hexanamide dimethanesulfonate
Summenformel
C16H29N3O4S
Molmasse
359.49

Namen und Synonyme

Lisdexamfetamine dimesylateVyvanse608137-33-3Lisdexamfetamine mesilateNRP-104SPD489Tyvenselis-dexamfetamine dimesylateNRP104SJT761GEGSNRP 104SPD-489
Weitere Namen anzeigen
LdxLisdexamfetamine mesylateLisdexamphetamine-DimesylateSpd 489Lisdexamfetamine (mesylate) (CRM)
Lisdexamfetamine dimesilateLisdexamphetamine dimesilateLisdexamfetamine dimethanesulfonateDTXSID60209653Dimesylate, Lis-dexamfetamineelvanseElvanse adultRefChem:57033

Datenbank-Bezeichner

CAS
608137-33-3
PubChem CID
11597697
DTXSID
DTXSID60209653
ChEMBL
CHEMBL1201178
UNII
SJT761GEGS

Eigenschaften

Berechnete Struktureigenschaften

Polarare Oberfläche (TPSA)
207 Ų
H-Brücken-Donoren
5
H-Brücken-Akzeptoren
9
Frei drehbare Bindungen
8
Schwere Atome
29
Formalladung
0
Komplexität
344

Experimentelle und physikochemische Eigenschaften

DrugsDEA NFLIS-Drug Category -> Phenethylamines (Amphetamines) (S)
Human Drugs · 3 Einträge

Breast Feeding; Lactation; Milk, Human; Adrenergic Agents; Central Nervous System Stimulants; Dopamine Agents; Sympathomimetics; Wakefulness-Promoting Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Physikochemische Eigenschaften

Flammpunkt
9 ℃ · 9℃
storage temp.
-20 °C · -20°C
Aggregatzustand
A neat solid

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Toxikologische Informationen

Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Lisdexamfetamine dimesylate

Ambiguous-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

wgk
1
ridadr
UN1230 - class 3 - PG 2 - Methanol, solution
risk_code
11-23/24/25-39/23/24/25
hazard_code
F,T
safety_code
7-16-36/37-45

Chemie und Industrie

Pharmakologische Informationen

FDA Pharmacological Classification · 4 Einträge

LISDEXAMFETAMINE DIMESYLATE

Central Nervous System Stimulation [PE]; Central Nervous System Stimulant [EPC]

LISDEXAMFETAMINE DIMESYLATE CAPSULES

Central Nervous System Stimulant [EPC]; Central Nervous System Stimulation [PE]

MeSH Pharmacological Classification · 2 Einträge

A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.

Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake.

Anwendungen · 2 Einträge

BeschreibungADHD is a neurobehavioral disorder characterized by varying degrees of inattention, hyperactivity, and impulsivity. ADHD is typically diagnosed in childhood and affects 7–12% of the pediatric population in the United States with the condition often enduring into adulthood. While the precise mechanism of action of lisdexamfetamine in treating ADHD is not known, amphetamines are believed to inhibit the reuptake of the neurotransmitters dopamine and noradrenaline (norepinephrine), thereby increasing their presynaptic availability and release into extraneuronal space. The prodrug is constructed by the condensation of D-amphetamine with the activated ester (N-hydroxysuccinimide) of bis-tert-butoxycarbonylprotected L-lysine. Lisdexamfetamine is ultimately generated by treatment with hydrochloric acid in dioxane. The most common adverse events, comparable to other amphetamine formulations, were decreased appetite, insomnia, upper abdominal pain, and irritability. Lisdexamfetamine is contraindicated in patients with advanced arteriosclerosis, symptomatic cardiovascular disease, moderate-to-severe hypertension, hyperthyroidism, known hypersensitivity to the sympathomimetic amines, glaucoma, a predisposition to agitated states, and a history of drug abuse. In addition, the drug should not be administered during or within 14 days of treatment with monoamine oxidase inhibitors. It has also been noted that psychostimulants may exacerbate symptoms of pre-existing psychotic disorders, so caution and close observation are recommended in this patient population.

Zugehörige Reaktionen

15
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 643241
HRID 643241als Produkt
Reaktionsgleichung von HRID 1441220
HRID 1441220als Produkt
Reaktionsgleichung von HRID 1442488
HRID 1442488als Produkt
Reaktionsgleichung von HRID 1442489
HRID 1442489als Produkt
Reaktionsgleichung von HRID 1443641
HRID 1443641als Produkt
Reaktionsgleichung von HRID 2234738
HRID 2234738als Produkt
Reaktionsgleichung von HRID 2237362
HRID 2237362als Produkt
Reaktionsgleichung von HRID 2239227
HRID 2239227als Produkt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

VerwendenTreatment of atten tion deficit hyperactivity disorder (ADHD).